News and Features

Global Philippines Fine Living

INVESTMENT STRATEGY

Economy Stocks Bonds Currencies

THE BASICS

Investment Tips Explainers Retirement

2024 Mid-Year Economi Briefing, economic growth in the Philippines

2024 Mid-Year Economic Briefing: Navigating the Easing Cycle

Investing with Love

Investing with Love: A Mother’s Guide to Putting Money to Work

retirement-ss-3

Investor Series: An Introduction to Estate Planning

September 1, 2023

View All Webinars

Inflation, economy, central bank, BSP, monetary policy, interest rates

Economic Updates

Monthly Economic Update: Back-to-back cuts

Stocks growth may be muted in the coming weeks

Reports

Back-to-back cuts: BSP follows Fed action

Economic Updates

Inflation settles at 2.5% despite food-price uptick   

View all Reports

Metrobank.com.ph Contact Us

Follow us on our platforms.

Login

Access Exclusive Content

Login to Wealth Manager

Economy 1 MIN READ

BRIEF-Shanghai Henlius Biotech Announces License Agreement With Getz Pharma For Rights Of Handayuan

February 23, 2022

By Reuters

Feb 23 (Reuters) – Shanghai Henlius Biotech Inc 2696.HK:

ANNOUNCES LICENSE AGREEMENT WITH GETZ PHARMA FOR RIGHTS OF HANDAYUAN
TO GRANT LICENSE TO GETZ PHARMA TO COMMERCIALISE ADALIMUMAB INJECTION IN PAKISTAN, PHILIPPINES, AMONG OTHER COUNTRIES

Further company coverage: 2696.HK

((Reuters.Briefs@thomsonreuters.com;))

This article originally appeared on reuters.com

Read More Articles About:

Worldwide News Philippine News Rates & Bonds Equities Economy Investment Tips Fine Living

Web Analytics